Literature DB >> 27500993

Rupatadine: global safety evaluation in allergic rhinitis and urticaria.

Vanesa González-Núñez1, Claus Bachert2, Joaquim Mullol3.   

Abstract

INTRODUCTION: Rupatadine is a second-generation H1-antihistamine with dual affinity for histamine H1 and PAF receptors. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria. AREAS COVERED: A Medline search was conducted to identify preclinical and clinical studies of rupatadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of rupatadine. EXPERT OPINION: The review of these data indicates that rupatadine is highly selective for histamine H1-receptors, exhibits additional PAF antagonism in in vitro and in vivo studies, does not cross the blood-brain barrier, and has similar adverse events comparable with other second-generation antihistamines. Rupatadine is a safe and well tolerated drug in patients over 2 years old, with no central nervous system or cardiovascular effects and it can be taken with or without foods.

Entities:  

Keywords:  H1-antihistamine; H1-receptor antagonist; PAF antagonist; Rupatadine; allergic rhinitis; chronic spontaneous urticaria; intermittent; perennial; persistent; pharmacodynamics; pharmacokinetics; safety; seasonal; second-generation antihistamine; therapeutic use; urticaria

Mesh:

Substances:

Year:  2016        PMID: 27500993     DOI: 10.1080/14740338.2016.1221399

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  7 in total

1.  Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats.

Authors:  Chunlei Li; Yanxia Fu; Yinyin Wang; Yanhua Kong; Mengdi Li; Danhui Ma; Wanli Zhai; Hao Wang; Yuting Lin; Sihan Liu; Fangli Ren; Jun Li; Yi Wang
Journal:  Cell Biochem Funct       Date:  2017-09-20       Impact factor: 3.685

Review 2.  Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications.

Authors:  Rosa M Muñoz-Cano; Rocio Casas-Saucedo; Antonio Valero Santiago; Irina Bobolea; Paula Ribó; Joaquim Mullol
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

3.  Incorporation of Ethylcellulose Microparticles Containing a Model Drug with a Bitter Taste into Nanofibrous Mats by the Electrospinning Technique-Preliminary Studies.

Authors:  Katarzyna Olechno; Nina Katarina Grilc; Špela Zupančič; Katarzyna Winnicka
Journal:  Materials (Basel)       Date:  2022-07-31       Impact factor: 3.748

Review 4.  Inflammation, not Cholesterol, Is a Cause of Chronic Disease.

Authors:  Alexandros Tsoupras; Ronan Lordan; Ioannis Zabetakis
Journal:  Nutrients       Date:  2018-05-12       Impact factor: 5.717

5.  Utilization of Ethylcellulose Microparticles with Rupatadine Fumarate in Designing Orodispersible Minitablets with Taste Masking Effect.

Authors:  Katarzyna Wasilewska; Patrycja Ciosek-Skibińska; Joanna Lenik; Stanko Srčič; Anna Basa; Katarzyna Winnicka
Journal:  Materials (Basel)       Date:  2020-06-15       Impact factor: 3.623

6.  Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis.

Authors:  Joaquim Mullol; Iñaki Izquierdo; Kimihiro Okubo; Giorgio Walter Canonica; Jean Bousquet; Antonio Valero
Journal:  Clin Transl Allergy       Date:  2019-10-09       Impact factor: 5.871

7.  Orodispersible Films with Rupatadine Fumarate Enclosed in Ethylcellulose Microparticles as Drug Delivery Platform with Taste-Masking Effect.

Authors:  Katarzyna Olechno; Bartosz Maciejewski; Klaudia Głowacz; Joanna Lenik; Patrycja Ciosek-Skibińska; Anna Basa; Katarzyna Winnicka
Journal:  Materials (Basel)       Date:  2022-03-14       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.